Enriched Eggs for Retina Health in Type 2 Diabetes
NCT04496817 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2023-11-02
Summary
Diabetes mellitus has been declared a major public health issue. Among the complications of the disease, retinopathy can have a significant impact on mobility and quality of life for individuals living with diabetes. As the leading cause of new blindness in adults, diabetic retinopathy has been shown to affect 23% of all Type 1 and 14% of Type 2 diabetic individuals. Various studies have reported that a number of components in the egg may contribute to visual function and eye health. Specifically, i) egg yolk naturally contains, and can be further enriched with the carotenoids lutein and zeaxanthin. Lutein and zeaxanthin protect the retina against light induced retinal damage by acting as potent antioxidants that shield the retina from harmful short-wave radiation. ii) eggs can also be enriched to provide a vehicle for specific nutrients to promote eye health including omega-3 fatty acid, docosahexaenoic acid (DHA). A substantial amount of DHA is uniquely found within the retina. A DHA deficiency has shown to induce abnormal retina function indicating a constant supply of this nutrient is necessary for retina health. Currently, the American Diabetes Association declares that eggs are an excellent choice for people with diabetes, but information lacks on the status of whole egg consumption in diabetic individuals in relation to their retinal health. Therefore, the current study aims to determine if the consumption of two lutein and DHA enriched eggs per day can safely improve the retina function of individuals with type 2 diabetes.
A total of 60 adult diabetic male and female participants will be recruited to take part in this double-blinded, randomized, placebo-controlled, parallel trial. Participants will be randomly assigned to include two DHA and lutein enriched eggs or regular eggs into their usual diet for 6 weeks. At the beginning and end of the trial, a variety of measures will be analyzed including blood lipid parameters, carotenoid status, anthropometrics, arterial stiffness, advanced glycated end products, macular pigment optical density and electroretinography. These measures will aid in determining whether enriched egg consumption can safely improve retina function, while not adversely effecting body composition and cardiovascular risk factors in individuals with diabetes. The results of this study will contribute to the development of valuable prevention strategies for eye health in individuals with diabetes, thereby improving their quality of life.
Conditions
Interventions
- OTHER
-
Docosahexaenoic Acid and Lutein Enriched Eggs
Consumption of 2 docosahexaenoic acid and lutein enriched eggs daily (at least 5 days our week) for 6 weeks
- OTHER
-
Regular Eggs
Consumption of 2 non enriched eggs daily (at least 5 days our week) for 6 weeks
Sponsors & Collaborators
-
Egg Farmers of Canada
collaborator UNKNOWN -
University of Manitoba
lead OTHER
Principal Investigators
-
Miyoung Suh, RD, PhD · University of Manitoba
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-07-11
- Primary Completion
- 2024-09-01
- Completion
- 2024-09-01
Countries
- Canada
Study Locations
More Related Trials
-
Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema
NCT02441907 ·Status: COMPLETED ·Phase: PHASE4
-
Laser and Antioxidant Treatment of Diabetic Macular Edema
NCT00055042 ·Status: COMPLETED ·Phase: PHASE1
-
A Systematic Study of Retinal Structure and Function in Diabetic Macular Oedema
NCT02876393 ·Status: COMPLETED
-
A Pilot Study to Assess the Preliminary Efficacy of EDTA Eye Drops on Band Keratopathy
NCT03985371 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Longitudinal Natural History Study of Retinal Function in Eyes of Patients With Diabetes
NCT07270133 ·Status: NOT_YET_RECRUITING
-
Safety of Trypan Blue on Endothelium of Diabetic Retinopathy Patients
NCT03755752 ·Status: COMPLETED ·Phase: NA
-
Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents
NCT06205979 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales
NCT06914778 ·Status: RECRUITING
-
Clinical Decision Support Algorithm to Predict Diabetic Retinopathy
NCT03769948 ·Status: UNKNOWN
-
Dyslipidemia and Diabetic Retinopathy
NCT03403283 ·Status: COMPLETED
-
Photobiomodulation for the Treatment of Diabetic Macular Edema
NCT02457975 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Real-time Eye Tracking and Imaging of the Eye in Diabetic Retinopathy Patients
NCT05608265 ·Status: COMPLETED ·Phase: NA
-
Vascular Reparative Mechanism in Diabetes
NCT02119689 ·Status: ACTIVE_NOT_RECRUITING
-
Genetic Markers and Proliferative Diabetic Retinopathy
NCT02879422 ·Status: COMPLETED ·Phase: NA
-
The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy
NCT01880372 ·Status: TERMINATED ·Phase: NA
-
Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery
NCT01988246 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Effect of Intracameral Dexamethasone After Phacoemulsification in Diabetics on Corneal Endothelial Cell Density
NCT03361709 ·Status: WITHDRAWN ·Phase: PHASE4
-
An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
NCT05566717 ·Status: UNKNOWN
-
Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
NCT03097068 ·Status: COMPLETED ·Phase: PHASE4
-
Oral Metformin for Treatment of ABCA4 Retinopathy
NCT04545736 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Fenofibrate in Type 2 Diabetes
NCT03829514 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema
NCT01168258 ·Status: TERMINATED
-
Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema
NCT02088229 ·Status: COMPLETED
-
Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy in Patients With Types 1 and 2 Diabetes Mellitus
NCT00287651 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy
NCT01213888 ·Status: TERMINATED ·Phase: NA